We are live on ! Find out more
BCM

BIOS Capital Management Portfolio holdings

AUM $52.9M
1-Year Est. Return 30.51%
This Fund
S&P 500
This Quarter Est. Return
+44.85%
1 Year Est. Return
+30.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$88.9M
AUM Growth
+$16.3M
Cap. Flow
+$364K
Cap. Flow %
0.41%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ACTU
Actuate Therapeutics
ACTU
+$616K

Top Sells

Rank Stock Value
1
LTRN icon
Lantern Pharma
LTRN
+$251K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACTU
1
Actuate Therapeutics
ACTU
$26.6M
$67.2M 75.62%
10,049,996
+84,917
+0.9% +$616K
CGTX icon
2
Cognition Therapeutics
CGTX
$79.6M
$8.1M 9.11%
6,000,000
– –
IRD
3
Opus Genetics
IRD
$306M
$6.59M 7.42%
3,683,429
– –
LTRN icon
4
Lantern Pharma
LTRN
$33.6M
$4.42M 4.97%
1,015,715
-60,237
-6% -$251K
RNTX
5
Rein Therapeutics
RNTX
$63.1M
$1.94M 2.19%
1,690,751
– –
INAB icon
6
IN8bio
INAB
$9.88M
$622K 0.7%
286,664
– –

Similar funds

FRGX
First Reserve GP XIII Stamford, Connecticut $52.9M AUM 17.37% 1-Year Est. Return
ICM
Irth Capital Management New York $52.8M AUM 21.11% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
GMEI
Global Media & Entertainment Investments Nassau, Bahamas $53M AUM 0% 1-Year Est. Return
TP
Toronado Partners San Francisco, California $53M AUM 13.38% 1-Year Est. Return
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53.2M AUM 13.56% 1-Year Est. Return
WEO
William E. Oberndorf $53.3M AUM 10.89% 1-Year Est. Return
NCM
Notable Capital Management Menlo Park, California $53.4M AUM 10.98% 1-Year Est. Return

BIOS Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, BIOS Capital Management held 6 positions worth $88.9M, up 23% from $72.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2025: portfolio turnover was 0%. BIOS Capital Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • BIOS Capital Management added most to Actuate Therapeutics in Q3 2025, an estimated $616K increase.
  • BIOS Capital Management's biggest Q3 2025 reduction was Lantern Pharma, cutting an estimated $251K.
  • BIOS Capital Management's ten largest holdings make up 100% of its $88.9M portfolio in Q3 2025.
  • BIOS Capital Management opened 0 new positions and closed 0 in Q3 2025.
  • BIOS Capital Management's portfolio value rose 23% quarter-over-quarter to $88.9M.

Based on BIOS Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.